Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2008 (2008), Article ID 727505, 5 pages
http://dx.doi.org/10.1155/2008/727505
Research Article

Antibiotic Resistance Patterns in Invasive Group B Streptococcal Isolates

1Infectious Disease Epidemiology, Prevention and Control Division, Minnesota Department of Health, 625 Robert Street North, P.O. Box 64975, Saint Paul, MN 55164, USA
2Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
3Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
4Streptococcus Laboratory, Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
5Pediatrics and Laboratory Medicine and Pathology, Clinical Microbiology Laboratory, University of Minnesota Medical School, 420 Delaware Street SE Minneapolis, MN 55455, USA
6Public Health Laboratory Division, Minnesota Department of Health, 601 Robert Street North, P.O. Box 64899, Saint Paul, MN 55164, USA
7Public Health Division, Oregon Department of Human Services, 800 NE Oregon Street, Portland, OR 97232, USA
8Atlanta Veterans Affairs Medical Center, Emory University School of Medicine, 1670 Clairmont Rd, Station 151 Decatur, GA 30033, USA
9Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, NY 12208, USA

Received 10 June 2008; Accepted 5 December 2008

Academic Editor: Reginald Sauve

Copyright © 2008 Mei L. Castor et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996–2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V ( ). Clindamycin resistance increased from 10.5% to 15.0% ( for trend 12.70; ); inducible clindamycin resistance was associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% ( for trend 55.46; ). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.